INDV

NASDAQ Healthcare

Indivior PLC - Ordinary Shares

Drug Manufacturers - Specialty & Generic

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

๐Ÿ“Š Market Data
Price$37.66
Volume3,161,867
Market Cap4.56B
RSI (14-Day)77.7 Overbought
200-Day MA$29.30
50-Day MA$31.98
52-Week High$40.02
52-Week Low$10.63
P/E Ratio19.31
Forward P/E10.99
Price / Book-31.65
๐ŸŽฏ Investment Strategy Scores

INDV scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 30/100โ–ฒ +10
High dividend yield + low volatility
๐Ÿš€ Moon Shot 2/100โ–ผ -39
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 8/100โ–ผ -1
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 93/100โ–ฒ +1
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (93/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿš€ Moon Shot (2/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find INDV in your text

Paste any article, transcript, or post โ€” the tool will extract INDV and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.